Introduction
Breast cancer is the most common cancer in women in Europe, currently aecting one in 12 (Black, 1994) . A series of genes has been identi®ed linking breast cancer with inherited mutations (BRCA1, BRCA2) (Miki et al., 1994; Tavtigian et al., 1996) as well as acquired mutations or gene ampli®cations in a series of oncogenes including HER-2 (Szollosi et al., 1995) , ras (Miyakis et al., 1998) , and myc (Visscher et al., 1997) . These oncogenes encode proteins that induce signals leading to cell transformation and proliferation. Development of breast tumours is also known to involve secretion of growth factors and cytokines such as TGFa (Davis and Snyderwine, 1995) , IGF-I (Janssen and Lamberts, 1998) , TGFb (Christeli et al., 1996) , PDGF (de Jong et al., 1998) , and persistent activation of these signalling pathways is considered a critical component of the mammary oncogenesis.
Tpl-2 gene encodes a serine threonine kinase, which is activated by provirus insertion in MoMuLV-induced rat T cell lymphomas and MMTV-induced mouse mammary carcinomas Erny et al., 1996) . Provirus insertion occurs between exon 7 and exon 8 giving rise to a protein with truncated carboxy-terminus. The truncated protein is highly oncogenic when overexpressed in the thymus of transgenic animals inducing thymomas (Ceci et al., 1997) and morphological transformation in SHOK and NIH3T3 cells (Miyoshi et al., 1991) . It is expressed in most tissues but at relatively low levels, including ovarian and mammary tissues (Ohara et al., 1995; Erny et al., 1996) . The human Tpl-2 homologue, known as Cot, was initially cloned by transfection of cDNA derived from the thyroid tumour cell line TCO-4 into the hamster cell line SHOK (Miyoshi et al., 1991) . In situ hybridization histochemistry in a series of cell lines and tumour tissues revealed that Tpl-2/cot was overexpressed in parotid gland, gastric and colonic gland tumours as well as in the colon adenocarcinoma cell lines SW40 and WiDr (Ohara et al., 1995) .
Tpl-2 kinase activates the MAPK and SAPK pathways (Salmeron et al., 1996; Ceci et al., 1997) and induces IL-2 and TNFa expression in T cell lines (Tsatsanis et al., 1998a; Ballester et al., 1998) by activating the transcription factors NFAT and NFkB (Tsatsanis et al., 1998b; Belich et al., 1999) . Both MAPK and SAPK pathways play an important role in the transduction of signals generated by growth factors produced in mammary epithelial neoplasms (Cowley et al., 1994; Johnson et al., 1996) . NFAT and NFkB are also key transcription factors for the activation of cytokines and growth factors (Rao et al., 1997; Royds et al., 1998) . Thus, deregulation of Tpl-2 kinase may induce signals that lead to cell transformation.
In the present study we analysed a series of breast tumours for overexpression of Tpl-2 mRNA. We identi®ed 14 out of 35 tumours with overexpression of Tpl-2. Eight out of 14 specimens representing increased Tpl-2 expression levels, exhibited gene ampli®cation, suggesting ampli®cation of the genomic locus of Tpl-2 as a possible mechanism for Tpl-2 overexpression. Overexpression of Tpl-2 was associated with early stages of the disease, suggesting that the activation of this oncogene is an early event in the development of breast cancer.
Results and discussion
Tpl-2 is overexpressed in human breast tumours Fourteen out of 35 breast tumours (40%) showed increased Tpl-2 expression levels as compared to their corresponding adjacent normal tissue (Table 1 ; Figures 1 and 2 ). Tpl-2 mRNA was expressed at 1.9 ± 7.4-fold higher levels in tumour samples than in normal mammary tissues.
In situ hybridization experiments demonstrated that mRNA expression of the Cot proto-oncogene was detected primarily in glandular tissues of the adult mouse (Ohara et al., 1995) . Since breast carcinomas contain an increased number of epithelial cells compared to normal breast tissues, we equalized for the presence of epithelial cells in our samples. Expression of cytokeratin 18 was used as a marker for epithelial cell content and the samples were equalized for its expression. b2 microglobulin was also used as control. Samples that showed overexpression of Tpl-2 mRNA compared to b2-microglobulin also showed overexpression compared to cytokeratin 18 at similar levels ( Table 1) . None of the specimens that indicated normal levels of Tpl-2 expression compared to b2-microglobulin showed overexpression compared to cytokeratin 18. The above observations con®rm that the overexpression of Tpl-2 in breast tumours is due to molecular alterations in the cancer cells and may be an important event towards tumour formation.
Tpl-2 is a potent serine threonine kinase which, when overexpressed, activates the MAPK and SAPK pathways and the transcription factors NFAT and NFkB. Activation of these pathways contributes to cell transformation and cell proliferation. The MAPKinases ERK1/ERK2 are activated by mitogens that aect breast cancer cells, such as IGF-I (Janssen and Lamberts, 1998) , and promote cell proliferation (Coutts and Murphy, 1998) . ERK2 is also activated by the growth inhibiting agent TPA. Activation of ERK2 by TPA can be inhibited by the MEK1/2 inhibitor PD98059 but the same inhibitor is unable to block insulin-dependent activation of ERK1/2 (Alblas et al., 1998) . Similarly, activation of ERK1/2 by Tpl-2 cannot be inhibited by PD98059 or a dominant II  I  I  I  II  III  II  II  I  III  III  I  I  I  III  II  I  II  I  II  I  II  I  II  II  III  II  II  III  II  II  II  II  II  II   III  II  II  II  I  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  II  III  II  II  II  II  II  II  II  II Tpl-2 overexpression in human breast cancer G Sourvinos et al negative MEK1 mutant (MEK1S621A) suggesting that Tpl-2 activates MAPK in a MEK1/2 independent fashion (Tsatsanis et al., 1998b) . Overexpression of Tpl-2 may, therefore, mimic or enhance the insulindependent signals towards cell proliferation.
In the present study we report for the ®rst time involvement of the Tpl-2 oncogene in human breast tumours. Overexpression of Tpl-2 was not signi®cantly associated with a particular histological subtype, tumour grade or with the age of the patients. Statistically signi®cant association was found between the overexpression of Tpl-2 and Stage I of the tumours (P=0.01), indicating that overexpression of Tpl-2 may be an early molecular event in the development of the disease.
Tpl-2 gene ampli®cation in human breast tumours
We tested whether the overexpression detected in the breast tumour specimens is linked to gene amplification. Of the 14 specimens that showed overexpression, eight also had the genomic locus of Tpl-2 ampli®ed ( Figure 3 ). We further tested for linkage between overexpression of Tpl-2 and ampli®cation of Tpl-2 locus, examining the incidence of allelic imbalance in breast cancer specimens using two microsatellite markers at chromosome 10p11.2, D10S1768 and D10S1555, located upstream and downstream of the Tpl-2 gene respectively. The detection of imbalance between the alleles in the tumour samples as compared to their corresponding normal alleles may provide evidence for the increased number of copies of this chromosomal region. Indeed, all eight samples exhibiting ampli®cation using the ®rst methodology displayed allelic imbalance for this microsatellite locus. The distance between the two markers is approximately 1 cm suggesting that the amplicon is larger than 1 cm. None of the samples with no ampli®cation exhibited allelic imbalance. Representative examples of specimens exhibiting allelic imbalance are shown in Figure 4 .
These results con®rm our ®rst observation showing gene ampli®cation in some of the samples overexpressing Tpl-2 which constitutes a possible mechanism for the elevated expression of the gene in breast cancer. Our results are consistent with previous studies, revealing increased copy numbers on chromosomal arm 10p in breast cancer (Ried et al., 1995; James et al., 1997; Murphy et al., 1995) .
Correlation of Tpl-2 overexpression and amplification was statistically signi®cant (P50.009) suggesting a possible mechanism for Tpl-2 overexpression in human breast tumours. No signi®cant correlation was found between gene ampli®cation and any clinicopathological parameters.
Expression of estrogen receptor (ER) or progesterone receptor (PR) in breast tumours overexpressing Tpl-2
The same set of breast tumours was analysed for the presence of ER and PR. Expression of ER is often linked to progression of breast cancers from a hormone-dependent, nonmetastatic, antiestrogen-sensitive phenotype to a hormone-independent, antiestrogen-and chemotherapy-resistant phenotype with invasive and metastatic properties (Ito et al., 1995) . One of the characteristics of the ER negative invasive breast cancer cells is constitutive high levels of NFkB activity. NFkB binding activity is normally low in the ER positive rat mammary carcinoma cell line RM22-F5 but it is signi®cantly enhanced when it progresses to the ER negative malignant phenotype (Nakshatri et al., 1997) . Since Tpl-2 activates NFkB in lymphoid cells we tried to de®ne a possible correlation between Tpl-2 overexpression and presence of estrogen receptor. Of the 14 cases where Tpl-2 was overexpressed, nine were found negative for the presence of ER and ®ve were positive for ER expression (Table 1) . Of the Tpl-2 nonoverexpressing tumours 13 were ER negative and eight ER positive, suggesting that there is no signi®cant correlation between the presence of estrogen receptors and overexpression of Tpl-2.
The above samples were also tested for the presence of progesterone receptor. PR is known to interact with the RelA subunit of NFkB and they are mutually repressed (Kalkhoven et al., 1996) . Tpl-2 is a potent activator of NFkB (Tsatsanis et al., 1998b; Belich et al., 1999) and the presence of Tpl-2 kinase may overrule the inhibitory eect of the PR. Among the 14 Tpl-2 overexpressing samples, ten were found positive for PR expression while four did not express the receptor, suggesting that there is a signi®cant correlation between Tpl-2 overexpression and presence of progesterone receptor (P=0.029). From the non Tpl-2 overexpressing samples seven were PR positive and 14 were PR negative. These observations indicate a requirement for high levels of Tpl-2 in the PR positive tumours. This suggests a possible mechanism for tumorigenesis in which Tpl-2 activates NFkB and Table 1 ), indicating that Tpl-2 may be an event that contributes to the tumour formation in patients that are otherwise considered of good prognosis.
In conclusion, we examined the expression of the Tpl-2 mRNA in human breast tumours. In 14 out 35 (40%) samples Tpl-2 was overexpressed. Overexpression was signi®cantly linked to gene ampli®cation. There was a signi®cant association with stage I tumours, indicating that Tpl-2 overexpression may be an early event in the development of breast cancer. Overexpression of Tpl-2 may be linked to expression of PR and in particular with the simultaneous expression of both PR and ER. The molecular mechanism through which Tpl-2 contributes to the development of breast cancer remains to be identi®ed.
Materials and methods

Tissue specimens
Thirty-®ve tumour specimens from breast cancer paired with their corresponding adjacent normal tissue were surgically obtained and frozen at 7708C (Sourvinos et al., 1997) . All the specimens corresponded to primary tumours. Clinical data (stage, grade, histological subtype, age) were available for all the specimens tested.
RNA and DNA extraction
Total RNA was isolated from fresh tissues using Trizol (Life Technologies) following the manufacturer's instructions. RNA samples were digested with DNasel (Gibco BRL) in order to discard genomic DNA. DNA from fresh tissues was extracted as previously described (Kiaris et al., 1994) and stored at 48C until PCR ampli®cation.
cDNA synthesis and PCR
For ®rst strand cDNA synthesis, 1 ± 5 mg of total RNA was reverse transcribed in a 20 ml reaction volume containing 2 ml of 106PCR buer, 50 ng random hexamers, 50 mM MgCl 2 , 200 ng dNTPs, 0.1 M DTT and 200 U Reverse Transcriptase, (SuperScript II RT, Life Technologies) for 50 min at 428C. PCR ampli®cation of cDNA was performed in a 50 ml reaction volume containing 1 mg cDNA, 1 mM of each primer, 200 ng dNTPs, 5 ml of 106buer (670 mM Tris.HCl, pH 8.5; 166 mM ammonium sulphate; 67 mM magnesium chloride; 1.7 mg/ml BSA; 100 mM b-mercaptoethanol and 1% (w/v) Triton X-100) and 1 U of Taq DNA polymerase. Tpl-2 speci®c cDNA sequence was ampli®ed using a pair of amplimers derived from dierent exons of the Tpl-2 gene, separated by an intron, to prevent ampli®cation of genomic DNA sequences that may contaminate cellular RNA preparations. The oligonucleotide primers for Tpl-2, derived from the Tpl-2/Cot sequence, were as follows: Tpl-2 (sense) 5'-CAG TAA TCA AAA CGA TGA GCG TTC TAA-3' and Tpl-2 (antisense) 5'-GAA -CAT CGG AAT CTA TTT GGT AAC GTC-3'. Only a small segment (227 bp) of Tpl-2 cDNA was ampli®ed, so that even signi®cantly degraded RNA could be used as template.
The PCR reactions were performed on a DNA thermal cycler (Perkin Elmer-Cetus Instruments, Norwalk, CT, USA). The PCR program consisted of 27 cycles as follows: denaturation at 948C for 40 s, annealing at 578C for 40 s and extension at 728C for 35 s. Cycles were preceded by incubation for 5 min at 948C to ensure full denaturation and at 728C after the ®nal cycle to ensure full extension of the product. Preliminary experiments had revealed the conditions in which the ampli®cation reaction remained in the exponential phase (data not shown) and thus the results could be used for quantitation of the template. Several negative control reactions were included in each experiment. Some of the negative controls contained water instead of cDNA and other control reaction mixtures contained aliquots of cDNA reaction mixtures that were prepared without the addition of RNA. Ten ml of the PCR product was electrophoresed through a 12% polyacrylamide gel, silver stained and the intensity of the bands was analysed by an image analysis system (Adobe Photoshop 5.0). The reproducibility of this protocol was evaluated by densitometric analysis of the PCR signal following ®ve separate RT from the same RNA sample run on two dierent days. Results indicate a maximum variation of 6% between each PCR product (data not shown).
The quantity and the quality of mRNA samples was normalized after the ampli®cation of a 120 bp fragment of b2 microglobulin (b2m) mRNA using the primers (sense) 5'-AAAGATGAGTATGCCTGCCG-3' and (antisense) 5'-ACTCAATCCAAATGCGGC-3' or cytokeratin 18 (263 bp fragment) using the primers CK18F 5'-AGA TTG C-CA GCT CTG GGT TGA C-3' and CK18R 5'-TCT CAT G-GA GTC CAG GTC GAT CT-3' at annealing temperature of 578C. The mRNA levels for Tpl-2 were expressed as the ratio of the intensity of the bands in tumour tissues versus the corresponding levels of normal tissues. Cancer cells have a cell-kinetic system in which the signal transduction pathway of oncogenes is induced. Thus, we arbitrarily considered as normal expression, levels lower than 1.5-fold and as overexpression levels higher than 1.5-fold in malignant specimens compared to corresponding normal tissues (Miyakis et al., 1998) .
Genomic PCR analysis for detection of gene ampli®cation
To determine whether the overexpression of Tpl-2 was due to gene ampli®cation or caused by other genetic events, genomic DNA was isolated from the same tissues and proceeded to PCR (Frye et al., 1989) . Since the genomic sequence of the human Tpl-2/cot gene is not known, we designed primers that ampli®ed a region at the 5' untranslated region of exon 1 of the Tpl-2 gene. The pair of primers used were (sense) 5'-AGA TGC AAT CTT CTT ACC GCG A-3' and (antisense) 5'-TCA GAC TCC TGG CTT TGC ACA-3', and ampli®ed a fragment of 136 bp. To eliminate the possibility of mRNA contamination, the DNA preparations were treated with RNAseH (Gibco BRL) for 20 min at 378C and ethanol precipitated and resuspended in TE. PCR analysis was carried out as described above. The PCR program consisted of 28 cycles as follows: denaturation at 948C for 40 s, annealing at 638C for 30 s and extension at 728C for 30 s. Cycles were preceded by incubation for 5 min at 948C to ensure full denaturation and 728C after the ®nal cycle to ensure full extension of the product. To establish conditions for ampli®cation of the Tpl-2 sequence at the exponential phase we performed kinetic analysis increasing the number of PCR cycles. Two-hundred ng of genomic DNA were ampli®ed for 23, 25, 27, 29, 31 and 33 PCR cycles. PCR products were separated on a 12% polyacrylamide gel which was then silver stained, photographed and scanned. Quantitation of the bands was performed by digital imaging of the bands (Adobe Photoshop 5.0). A graph correlating densitometric units and number of PCR cycles was created to determine the exponential phase of the reaction ( Figure 5) . Our results revealed an exponential range between 26 and 30 PCR cycles. Thus, we carried out 28 PCR cycles in breast samples for the detection of gene ampli®cation. The ratio between Tpl-2 PCR products from tumour and the corresponding normal samples was determined by dividing the densitometric area of the tumour band by that of the normal band. In this procedure g-interferon (g-IFN) gene was used as a reference gene. The sequences of the oligonucleotides used were g-INF (sense) 5'-AGT GAT GGC T-GA ACT GTC GC-3' and g-INF (antisense) 5'-CTG GGA TGC TCT TCG ACC TC-3' yielding a 85 bp PCR product (Neubauer et al., 1992) . The reproducibility of the PCR in the gene ampli®cation analysis was tested performing three separate reactions for each sample on the same day. The densitometric analysis of the silver stained gels showed deviation of no more than 7% (data not shown).
Allelic imbalance analysis The DNA samples were examined for allelic imbalance at Tpl-2 locus, using two highly polymorphic microsatellite markers, D10S1768 and D10S1555 which are located upstream and downstream of the Tpl-2 gene, respectively. Oligonucleotide primers for D10S1555 were sense 5'-TGT TCC CGA TCA AAC A-GA GT-3' and anti-sense 5'-TTT CTG TGT CAA TTC T-CA GCC-3' while for D10S1768 were sense 5'-CTG TGG GCT ATC TGG GGT CA-3' and antisense 5'-GCC ACA CAC TGA GAA TGC CA-3'. PCR analysis was performed in a 50 ml reaction volume as described above. The reactions were denatured for 5 min at 948C and the DNA was subsequently ampli®ed for 28 cycles at 948C, 558C and 728C each step. Ten ml of the PCR product was analysed in a 12% polyacrylamide gel and stained with silver staining. Gels were scanned and the intensity of the bands corresponding to the microsatellite alleles was quantitated by a UVP image analysis system (Adobe Photoshop 5.0). Allelic imbalance was scored as a signi®cant dierence (440%) in the intensity of one allele 
Expression of estrogen receptor or progesterone receptor in breast tumours
The same set of breast tumours was analysed for the presence of ER and PR receptor status. Samples exhibiting ER or PR levels above 5 fmol/mg protein were considered as ER or PR positive, whereas specimens displaying ER or PR levels below 5 fmol/mg protein were considered as ER and PR negative, respectively.
Statistical analysis
Statistical analyses were performed using the w 2 -test or Fisher's exact test. One-tailed P-values 50.05 were considered statistically signi®cant.
